# 1cell.ai

OncoIndx / OncoTarget / Prime Plus — Multi-omic oncology product suite.

Source: https://en.bioecon.ru/companies/1cellbio/
Updated: 2026-07-20

- Country: India

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $16 million Series A raised on November 22, 2024 | https://inc42.com/company/1cell-ai/, https://techcrunch.com/2024/11/20/onecell-diagnostics-bags-16m-to-help-limit-cancer-recurrence-using-ai/ |
| Certification | CAP accredited, CLIA certified, NABL accredited, and ISO certified lab | https://1cell.ai/in/, https://1cell.ai/in/multi-modal-genomic-profiling/ |
| Headcount | approximately 174-191 employees as of 2026 | https://techcrunch.com/2024/11/20/onecell-diagnostics-bags-16m-to-help-limit-cancer-recurrence-using-ai/ |
| Revenue | ₹41.9 crore (approx. $5M USD) for the financial year ending March 31, 2025 | https://inc42.com/company/1cell-ai/ |
| Production site | Pune, India | https://techcrunch.com/2024/11/20/onecell-diagnostics-bags-16m-to-help-limit-cancer-recurrence-using-ai/ |

Independent sources: inc42.com, techcrunch.com

## Technologies

- [Multi-omics diagnostic panels for precision oncology](https://en.bioecon.ru/technology/multi-omics-diagnostic-panels-precision-oncology/)